2024-518138-10-00招募中2 期
Analysis of the efficacy and safety of two combination treatment regimens of nivolumab and ipilimumab in patients with dMMR and / or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)
Association Gercor19 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2025年1月9日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 93
- 试验地点
- 19
- 主要终点
- The co-primary endpoint of this study is Grade 3 or 4 TRAEs during the first 24 weeks (NCI CTCAE v5.0) and PFS at week 24
研究概览
简要总结
- To assess the safety (grade 3 or 4 TRAEs) profile according to NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 of two different combination schemes of nivolumab plus ipilimumab during the first 24 weeks of treatment,
- To assess PFS at week 24 for two combination schemes.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Signed and dated patient informed consent form (ICF) and willingness to comply with all study procedures and availability for the study duration
- •Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 7 days prior to initiation of study treatment: - Hematological status: White blood cell > 2000/μL; o Neutrophils > 1500/μL; o Platelets > 100.000/μL; o Hemoglobin > 9.0 g/dL; - Adequate renal function: o Serum creatinine level < 150 μM; - Adequate liver function: o Serum bilirubin ≤ 1.5 x upper normal limit (ULN); o Alkaline phosphatase (ALP) ≤ 3 x ULN; o Alanine aminotransferase (ALT) ≤ 3.0 x ULN; o Aspartame aminotransferase (AST) ≤ 3.0 x ULN; o Prothrombin time (PT)/International normalized ratio (INR) and partial PT (PTT) ≤ 1.5 x ULN unless participants are receiving anticoagulant therapy and their INR is stable and within the recommended range for the desired level of anticoagulation,
- •Females of childbearing potential must have negative urine or serum pregnancy test within 7 days before starting study treatment,
- •Women of childbearing potential should use effective contraception during treatment and 5 months thereafter. Males should use condoms during treatment and 7 months thereafter,
- •Registration in a national health care system (Protection Universelle Maladie [PUMa] included)
- •Age ≥ 18 years
- •ECOG PS of 0, 1, or 2
- •Histologically or cytologically confirmed colorectal adenocarcinoma
- •Documented advanced or metastatic disease not suitable for complete surgical resection
- •At least one measurable lesion as assessed by CT-scan or magnetic resonance imaging (MRI) according to RECIST v1.1 and feasibility of repeated radiological assessments. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
- •dMMR and/or MSI tumor status defined by: - Loss of MMR protein expression using immunohistochemistry with four (anti-MLH1, anti-MSH2, anti-MSH6, and anti-PMS2) antibodies, NB: if loss of only one protein, necessary to have PCR - and/or ≥ two instable markers by pentaplex polymerase chain reaction (BAT-25, BAT-26, NR-21, NR-24, and NR-27), NB: if two instable markers in the pentaplex panel, it is required to present confirmation of the dMMR status by immunohistochemistry or a comparison of the tumor PCR test with matched normal tissue, NB: Agreement of the Sponsor (GERCOR) is mandatory to include the patient (the patient’s file will be verified to confirm MSI/dMMR status before inclusion [an anonymized fax] and confirmation of a patient’s allocation will be sent by mail to the Investigator within 24h)
- •No or one prior line of systemic treatment for metastatic disease: - No prior systemic treatment; if patient received neoadjuvant/adjuvant therapy this therapy should be completed > 6 months prior the diagnosis of metastatic or recurrent disease is made, - Maximum one prior line of systemic treatment; if patient received one prior line of systemic therapy in the metastatic setting and experienced progression or patient received neoadjuvant/adjuvant therapy and experienced recurrence within ≤ 6 months after completion of therapy
- •Availability of a representative tumor specimen for exploratory translational research; tumor tissue specimens, either formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue sections (minimum of 30 positively charged slides) from primary or metastatic site must be submitted to the central laboratory
排除标准
- •Known brain metastases or leptomeningeal metastases
- •Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
- •Prior malignancy active within the previous 3 years except for: - Locally curable cancers that have been apparently cured (e.g. squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast); - Lynch syndrome-related non-colorectal cancer in complete remission for > 1 year
- •Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test prior to randomization) virus (HBV) or hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection. Patients with past HBV infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen antibody test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction testing is negative for HCV ribonucleic acid.
- •Prior allogeneic bone marrow transplantation or prior solid organ transplantation
- •Any serious or uncontrolled medical disorder that, in the opinion of Investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results
- •Known allergy/hypersensitivity to any component of study agents
- •Administration of a (attenuated) live vaccine within 28 days of planned start of study therapy of known need for this vaccine during treatment
- •Patient on tutelage or guardianship or under the protection of justice.
- •Persistence of toxicities related to prior chemotherapies grade > 1 (NCI CTCAE v5.0; except alopecia, fatigue, or peripheral sensory neuropathy, which can be grade 2)
- •Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, radiotherapy, immunotherapy)
- •Major surgical procedure within 4 weeks prior to initiation of study treatment
- •Prior treatment with an anti-PD1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents
- •Patients receiving any investigational drug, biological, immunological therapy within the previous 28 days before study treatment
- •Impossibility of submitting to the medical follow-up of the study for geographical, social or psychic reasons
- •Patients with an active, known or suspected autoimmune disease. Patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to be enrolled
- •History of interstitial lung disease or pneumonitis
结局指标
主要结局
The co-primary endpoint of this study is Grade 3 or 4 TRAEs during the first 24 weeks (NCI CTCAE v5.0) and PFS at week 24
The co-primary endpoint of this study is Grade 3 or 4 TRAEs during the first 24 weeks (NCI CTCAE v5.0) and PFS at week 24
次要结局
- PFS and ORR at weeks 24 and 48, and at 2 years (iRECIST)
- OS at weeks 24 and 48, and at 2 years
- AEs (NCI CTCAE v5.0)
- Treatment and iAEs
- Percentage of patients who received immune modulating concomitant medication (e.g., corticosteroids, infliximab, mycophenolate mofetil)
- Percentage of patients who received hormonal replacement therapy for immune-related endocrine toxicities
- Median time to onset, median time to resolution of SAEs and TRAEs (grade 3-4)
- Score changes in EORTC QLQ-C30 and NCI-PRO-CTCAE scales
- ORR at weeks 24 and 48, and at 2 years (RECIST v1.1)
- PFS at week 48 and at 2 years (RECIST v1.1)
研究者
Dr GARCIA-LARNICOL
Scientific
Association Gercor
研究点 (19)
Loading locations...
相似试验
尚未招募
不适用
Identifying the minimal dose and optimal combination of high-intensity aerobic interval training (HIIT) and strength training to improve physical fitness and cardiometabolic risk markers in sedentary adults – a randomized-controlled pilot and feasibility studyPrevention: physical fitness and cardiometabolic risk in sedentary adultsDRKS00012688niversitätsklinikum Mannheim40
已完成
不适用
Dose finding for a safe and efficacious combination of chloroquine (CQ) and methylene blue in the treatment of uncomplicated falciparum malaria in young children of Burkina Fasoncomplicated falciparum malariaInfections and InfestationsMalariaISRCTN36731786DSM Fine Chemicals (Austria)576
招募中
1 期
Dose finding study for deciding the optimal dose of fluorescein during probe based confocal endomicroscopyJPRN-UMIN000027696ational Cancer Center Hospital24
尚未招募
不适用
Aproach to optimize the dose of contrasut medicum considering patient's blood flow on CTA.JPRN-UMIN000027046Ryukyu unversity hospital50
招募中
不适用
Investigation of the maximum optimal dosage and efficacy of lenalidomide for the treatment of relapsed and refractory multiple myeloma.multiple myelomaJPRN-UMIN000010178Kurume University Hospital Division of Hematology and Oncology38